None listed
Conditions
Brief summary
fibrocystic disease of breast is common health problem which not well understood and not well attended. with the rising awareness about breast cancer in female population there is a colossal number of female reporting to breast clinic with signs and symptoms of fibrocystic breast disease. we feel the need that this condition must be presented in effective way to reduce repetitive presentation. Metformin can be a effective solution. metformin has been high lighted in western studies for its effectiveness in fibrocystic disease.
Interventions
the intervention group will be prescribed Oral metformin in a dose of 500 mg twice daily along with paracetamol 1000 mg PRN for pain relief when required not exceeding 4 grams /day for a period of 3 months. The control group will only be prescribed paracetamol in the dose of 100mg PRN or as required not exceeding 4grams/day for three months . All patients will be asked for follow up at 3 weekly intervals they will be given a call to reach on appointment day on the morning of booked appointme
the intervention group will be prescribed Oral metformin in a dose of 500 mg twice daily along with paracetamol 1000 mg PRN for pain relief when required not exceeding 4 grams /day for a period of 3 months. The control group will only be prescribed paracetamol in the dose of 100mg PRN or as required not exceeding 4grams/day for three months . All patients will be asked for follow up at 3 weekly intervals they will be given a call to reach on appointment day on the morning of booked appointment.. At each follow-up, compliance with medication would be verbally confirmed from all patients.. Pain relief would be assessed on visual analogue score (VAS) while Ultrasound study would be performed to assess the number and size pf the cystic cluster in the affected breast(s) and compare with the baseline ultrasound and visual analogue scale.
Sponsors
DR ALMAS AFRIDI KHYBER TEACHING HOSPITAL PESHAWAR
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator)
Eligibility
Sex/Gender
All
Age
25 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
all women with child bearing age and diagnosed fibrocystic disease on ultrasound of the breast
Exclusion criteria
*patient with active arthritis or musculoskeletal condition as it confounding factor *male gender *women who are lactating or pregnant
Outcome results
None listed